ReproCELL Incorporated (4978.T)
JPY 103.0
(0.0%)
JPY 103.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.24 Million JPY | -220.8% |
| 2022 | -254.58 Million JPY | 73.54% |
| 2021 | -513.84 Million JPY | 42.77% |
| 2020 | -726.2 Million JPY | 8.63% |
| 2019 | -924.65 Million JPY | -46.95% |
| 2018 | -550.1 Million JPY | 15.95% |
| 2017 | -2.02 Billion JPY | 0.89% |
| 2016 | -681.6 Million JPY | 16.84% |
| 2015 | -1.65 Billion JPY | -167.45% |
| 2014 | -314.22 Million JPY | -151.99% |
| 2013 | -122.21 Million JPY | -784.92% |
| 2012 | 17.84 Million JPY | 121.4% |
| 2011 | -83.39 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -107 Million JPY | -54.74% |
| 2023 Q1 | 82.91 Million JPY | 172.5% |
| 2023 FY | - JPY | -220.8% |
| 2023 Q4 | -110.4 Million JPY | -819.38% |
| 2023 Q3 | -12 Million JPY | -0.75% |
| 2023 Q2 | -11.92 Million JPY | -114.38% |
| 2022 Q1 | 43.01 Million JPY | 129.05% |
| 2022 FY | - JPY | 73.54% |
| 2022 Q4 | -114.36 Million JPY | -7.2% |
| 2022 Q3 | -106.68 Million JPY | -492.47% |
| 2022 Q2 | 27.18 Million JPY | -36.81% |
| 2021 FY | - JPY | 42.77% |
| 2021 Q4 | -148.08 Million JPY | 0.98% |
| 2021 Q3 | -149.55 Million JPY | -88.66% |
| 2021 Q2 | -79.27 Million JPY | 35.09% |
| 2021 Q1 | -122.12 Million JPY | 19.6% |
| 2020 Q2 | -157.55 Million JPY | 24.18% |
| 2020 FY | - JPY | 8.63% |
| 2020 Q1 | -207.8 Million JPY | 15.89% |
| 2020 Q3 | -291.99 Million JPY | -85.33% |
| 2020 Q4 | -151.89 Million JPY | 47.98% |
| 2019 Q3 | -221.88 Million JPY | -8.23% |
| 2019 FY | - JPY | -46.95% |
| 2019 Q4 | -247.07 Million JPY | -11.35% |
| 2019 Q1 | -229.53 Million JPY | -34.49% |
| 2019 Q2 | -205 Million JPY | 10.69% |
| 2018 FY | - JPY | 15.95% |
| 2018 Q4 | -170.67 Million JPY | 16.57% |
| 2018 Q3 | -204.56 Million JPY | -32.91% |
| 2018 Q2 | -153.91 Million JPY | -58.56% |
| 2018 Q1 | -97.06 Million JPY | 67.1% |
| 2017 Q1 | -196.67 Million JPY | 48.38% |
| 2017 Q4 | -295.02 Million JPY | -31.61% |
| 2017 Q3 | -224.16 Million JPY | 6.96% |
| 2017 Q2 | -240.94 Million JPY | -22.51% |
| 2017 FY | - JPY | 0.89% |
| 2016 Q1 | -351.93 Million JPY | 27.76% |
| 2016 FY | - JPY | 16.84% |
| 2016 Q4 | -381.02 Million JPY | -1150.27% |
| 2016 Q3 | 36.27 Million JPY | 114.56% |
| 2016 Q2 | -249.22 Million JPY | 29.18% |
| 2015 Q3 | -272.66 Million JPY | 7.44% |
| 2015 Q2 | -294.57 Million JPY | -165.02% |
| 2015 Q1 | -111.15 Million JPY | 11.67% |
| 2015 Q4 | -487.17 Million JPY | -78.67% |
| 2015 FY | - JPY | -167.45% |
| 2014 Q1 | -39.81 Million JPY | -26.5% |
| 2014 Q4 | -125.84 Million JPY | 35.39% |
| 2014 Q3 | -194.76 Million JPY | -125.02% |
| 2014 Q2 | -86.55 Million JPY | -117.38% |
| 2014 FY | - JPY | -151.99% |
| 2013 FY | - JPY | -784.92% |
| 2013 Q3 | -25.77 Million JPY | 36.98% |
| 2013 Q1 | -34.41 Million JPY | 0.0% |
| 2013 Q2 | -40.89 Million JPY | -18.82% |
| 2013 Q4 | -31.47 Million JPY | -22.14% |
| 2012 FY | - JPY | 121.4% |
| 2011 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 99.139% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 101.689% |
| GNI Group Ltd. | 14.48 Billion JPY | 99.943% |
| Linical Co., Ltd. | 1.24 Billion JPY | 99.339% |
| Trans Genic Inc. | 240.95 Million JPY | 96.578% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 100.608% |
| Soiken Holdings Inc. | -583.2 Million JPY | 101.414% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 101.367% |
| AnGes, Inc. | -8.86 Billion JPY | 100.093% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 100.641% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 100.111% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 93.564% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 100.955% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 100.755% |
| CanBas Co., Ltd. | 53.65 Million JPY | 84.632% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 101.063% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 107.375% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 100.68% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 100.597% |
| PeptiDream Inc. | 7.37 Billion JPY | 99.888% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 100.427% |
| Ribomic Inc. | -1.01 Billion JPY | 100.814% |
| SanBio Company Limited | -4.52 Billion JPY | 100.182% |
| Healios K.K. | -3 Billion JPY | 100.274% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 100.707% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 100.592% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 100.588% |
| StemRIM | -2.03 Billion JPY | 100.406% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 99.369% |
| FunPep Company Limited | -952 Million JPY | 100.866% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 100.928% |
| Stella Pharma Corporation | -723.85 Million JPY | 101.139% |
| TMS Co., Ltd. | -937 Million JPY | 100.88% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 101.063% |
| Cuorips Inc. | -518 Million JPY | 101.592% |
| K Pharma,Inc. | 366.05 Million JPY | 97.748% |
| Takara Bio Inc. | 8.02 Billion JPY | 99.897% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 90.624% |
| StemCell Institute Inc. | 534.35 Million JPY | 98.457% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 96.632% |
| CellSeed Inc. | -836.51 Million JPY | 100.986% |